We are live on ! Find out more
TENX icon

Tenax Therapeutics

19 hedge funds and large institutions have $30.1M invested in Tenax Therapeutics in 2014 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

6% more funds holding

Funds holding: 1819 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

22% less capital invested

Capital invested by funds: $38.5M → $30.1M (-$8.33M)

99% less call options, than puts

Call options by funds: $12K | Put options by funds: $1.98M

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.55%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
4
Increased
4
Reduced
3
Closed
3
Calls
$12K
Puts
$1.98M
Net Calls
-$1.97M
Net Calls Change
+$1.27M

TENX Hedge Fund Activity: Q3 2014 in Review

19 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q3 2014, worth a combined $30.1M — down 22% from $38.5M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new TENX positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.

The largest buyer was RA Capital Management, adding an estimated $8.09M. The largest seller was Great Point Partners, cutting an estimated $3.98M.

  • 19 institutional investors held Tenax Therapeutics (TENX) as of Q3 2014, up from 18 in Q2 2014.
  • Funds reported $30.1M of Tenax Therapeutics stock for Q3 2014, down 22% quarter-over-quarter.
  • 4 funds opened new Tenax Therapeutics positions in Q3 2014 and 3 closed out, a net change of +1 holder.
  • The largest Tenax Therapeutics buyer in Q3 2014 was RA Capital Management, an estimated $8.09M added.
  • The largest Tenax Therapeutics seller in Q3 2014 was Great Point Partners, an estimated $3.98M sold.

Based on aggregated 13F filings for Q3 2014.